KFSYSCC Takes the Lead in Introducing Precision Cancer Drug Dispensing System Equipment
KFSYSCC, in collaboration with Neteris Pharmaceuticals, Mingyi Technology, and National Yang Ming Chiao Tung University, has successfully developed a pioneering system, setting a new benchmark for patient medication safety.
Accuracy and quality are the highest goals and basic thresholds in medical operations! In the chemotherapy plans for cancer patients, precise drug dispensing is as crucial as the correct evidence-based prescription of anticancer drugs. KFSYSCCl, which has been focusing on cancer treatment for over 30 years, has teamed up with National Yang Ming Chiao Tung University, Neteris Pharmaceuticals, and Mingyi Technology to jointly develop a Drug Dispensing System. Utilizing digital health technology, the system allows for precise chemotherapy dispensing directed by a physician’s prescription, significantly reducing errors or discrepancies due to manual interpretation of prescriptions and manual drug extraction. This advancement considerably improves the accuracy and reliability of medication used in cancer chemotherapy, ensuring the efficacy and safety of patient medication.
According to research data from the American Journal of Health-System Pharmacy (AJHP) on five representative hospitals in the United States, the error rate for manually compounded drugs averages 9%, with about 2% of these errors posing serious potential clinical risks. "These should not occur, although in the vast majority of cases they do not affect the patient, we strive for the best and commit to a zero-error rate for our patients!" expressed Dr. Andrew T. Huang, Director of KFSYSCC.
This sterile drug compounding process management system (IV-WMS) integrates an Automatic Optical Inspection (AOI) system for compounding, with every step rigorously monitored and recorded, significantly reducing human error. The system also features robust traceability; every compounding step is documented and uploaded to the hospital’s Electronic Medical Record (EMR) system. This establishes a comprehensive medication record from prescription, drug batch number, compounding process, delivery timing, to administration. In the future, integration with AI prescription interpretation is planned.
"The closed system infusion system (CSTD) developed by Nedilist Corporation, through deep collaboration with KFSYSCC, Ming Yi Technology, and Yangming Jiaotong University, has successfully helped pharmacists complete drug compounding tasks more safely and accurately," stated Chien Zhiwei, General Manager of Nedilist. This collaboration has fully demonstrated the safety and user-friendliness of the CSTD system, moving hospital pharmacy operations towards smart and automated processes.
"In the drug compounding process, pharmacists bear the ultimate confirmation work," said Yang Hongren, COO of Ming Yi Technology. The goal of automation is not to replace pharmacists; in fact, the expertise of pharmacists cannot be replaced by machines. The purpose of this equipment is to assist pharmacists in achieving a more efficient, accurate, and safer compounding process.
"Pharmacists have been distracted from their true expertise due to the heavy and repetitive nature of compounding tasks," expressed Jiang Shaoqing, Deputy Director of the Pharmacy Department at KFSYSCC and Assistant Professor at Yangming Jiaotong University. By introducing the NM automated compounding system, the physical and mental burden on pharmacists is reduced, allowing them to focus more on understanding patients, confirming prescription validity, and tracking patient medication usage. This is KFSYSCC pharmacists' commitment to ensuring patient medication safety and efficacy. "This is the most important purpose of our many years of professional training!" emphasized Jiang Shaoqing.
KFSYSCC is Taiwan's only specialty cancer hospital. For 33 years, it has always centered its work around patient care and safety, achieving remarkable cancer treatment outcomes with a five-year survival rate for all cancer stages at 75%, and 72% for invasive cancer. This is significantly higher compared to the overall five-year survival rate of 56% across other hospitals in Taiwan. The recent innovative collaboration in the medical field with the Medication Precision Dispensing System marks a step up in Taiwan’s medical technology sector. The Medication Precision Dispensing System is also set to be gradually introduced globally, allowing medical institutions and patients around the world to benefit from more effective, safer, and more precise cancer medication.
